Skip to Main Content

Over the past six months, more drug makers have begun posting their policies for gaining greater access to experimental medicines, according to a new analysis. However, more than half of all pharmaceutical manufacturers have yet to take this step to improve disclosure.

Specifically, 47 percent of 98 drug makers have posted a compassionate use policy on their web sites, compared with 19 percent last October. However, 84 percent of the 25 companies with a market capitalization of greater than $10 billion posted policies. This was up from 52 percent last fall.


There was also greater disclosure among medium-sized drug makers with market caps between $1.5 billion and $10 billion, with 52 percent posting policies, up from 14 percent last fall. And among small companies with market caps below $1.5 billion, 24 percent posted compared with 4 percent.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • “Drug makers must agree to make their medicines available”. Ed, at this point I believe that companies can still opt to post “no access” on their website, so that I don’t think this statement is entirely correct.

Comments are closed.